307 related articles for article (PubMed ID: 25703647)
1. Topical administration of a connexin43-based peptide augments healing of chronic neuropathic diabetic foot ulcers: A multicenter, randomized trial.
Grek CL; Prasad GM; Viswanathan V; Armstrong DG; Gourdie RG; Ghatnekar GS
Wound Repair Regen; 2015; 23(2):203-12. PubMed ID: 25703647
[TBL] [Abstract][Full Text] [Related]
2. The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial.
Ghatnekar GS; Grek CL; Armstrong DG; Desai SC; Gourdie RG
J Invest Dermatol; 2015 Jan; 135(1):289-298. PubMed ID: 25072595
[TBL] [Abstract][Full Text] [Related]
3. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
O'Meara S; Cullum N; Majid M; Sheldon T
Health Technol Assess; 2000; 4(21):1-237. PubMed ID: 11074391
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers.
Hanft JR; Pollak RA; Barbul A; van Gils C; Kwon PS; Gray SM; Lynch CJ; Semba CP; Breen TJ
J Wound Care; 2008 Jan; 17(1):30-2, 34-7. PubMed ID: 18210954
[TBL] [Abstract][Full Text] [Related]
5. A Prospective, Descriptive Study to Assess the Clinical Benefits of Using Calendula officinalis Hydroglycolic Extract for the Topical Treatment of Diabetic Foot Ulcers.
Buzzi M; de Freitas F; Winter M
Ostomy Wound Manage; 2016 Mar; 62(3):8-24. PubMed ID: 26978856
[TBL] [Abstract][Full Text] [Related]
6. Topical Erythropoietin Accelerates Wound Closure in Patients with Diabetic Foot Ulcers: A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial.
Hamed S; Ullmann Y; Belokopytov M; Shoufani A; Kabha H; Masri S; Feldbrin Z; Kogan L; Kruchevsky D; Najjar R; Liu PY; Kerihuel JC; Akita S; Teot L
Rejuvenation Res; 2021 Aug; 24(4):251-261. PubMed ID: 33504262
[TBL] [Abstract][Full Text] [Related]
7. A Prospective, Randomized, Multicenter, Controlled Evaluation of the Use of Dehydrated Amniotic Membrane Allograft Compared to Standard of Care for the Closure of Chronic Diabetic Foot Ulcer.
Snyder RJ; Shimozaki K; Tallis A; Kerzner M; Reyzelman A; Lintzeris D; Bell D; Rutan RL; Rosenblum B
Wounds; 2016 Mar; 28(3):70-7. PubMed ID: 26978860
[TBL] [Abstract][Full Text] [Related]
8. Topical application of the bee hive protectant propolis is well tolerated and improves human diabetic foot ulcer healing in a prospective feasibility study.
Henshaw FR; Bolton T; Nube V; Hood A; Veldhoen D; Pfrunder L; McKew GL; Macleod C; McLennan SV; Twigg SM
J Diabetes Complications; 2014; 28(6):850-7. PubMed ID: 25239451
[TBL] [Abstract][Full Text] [Related]
9. The impact of topical phenytoin on recalcitrant neuropathic diabetic foot ulceration.
El-Nahas M; Gawish H; Tarshoby M; State O
J Wound Care; 2009 Jan; 18(1):33-7. PubMed ID: 19131916
[TBL] [Abstract][Full Text] [Related]
10. Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers: A Phase 3 Randomized Clinical Trial.
Rastogi A; Kulkarni SA; Agarwal S; Akhtar M; Arsule S; Bhamre S; Bhosle D; Desai S; Deshmukh M; Giriraja KV; Jagannath J; Kashiva RY; Kesavan R; Khandelwal D; Kolte S; Kongara S; Darivemula AK; Madhusudan C; Pyare Saheb Qureshi MAH; Ramu M; Rathod G; Yalamanchi SR; Shakya S; Shetty P; Singh S; Deshpande SK; Viswanathan V; Unnikrishnan AG
JAMA Netw Open; 2023 May; 6(5):e2311509. PubMed ID: 37184839
[TBL] [Abstract][Full Text] [Related]
11. Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study.
Kaur R; Tchanque-Fossuo C; West K; Hadian Y; Gallegos A; Yoon D; Ismailyan L; Schaefer S; Dahle SE; Isseroff RR
Trials; 2020 Jun; 21(1):496. PubMed ID: 32513257
[TBL] [Abstract][Full Text] [Related]
12. A clinical trial of Integra Template for diabetic foot ulcer treatment.
Driver VR; Lavery LA; Reyzelman AM; Dutra TG; Dove CR; Kotsis SV; Kim HM; Chung KC
Wound Repair Regen; 2015; 23(6):891-900. PubMed ID: 26297933
[TBL] [Abstract][Full Text] [Related]
13. Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study.
Fife C; Mader JT; Stone J; Brill L; Satterfield K; Norfleet A; Zwernemann A; Ryaby JT; Carney DH
Wound Repair Regen; 2007; 15(1):23-34. PubMed ID: 17244316
[TBL] [Abstract][Full Text] [Related]
14. The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial.
Squadrito F; Bitto A; Altavilla D; Arcoraci V; De Caridi G; De Feo ME; Corrao S; Pallio G; Sterrantino C; Minutoli L; Saitta A; Vaccaro M; Cucinotta D
J Clin Endocrinol Metab; 2014 May; 99(5):E746-53. PubMed ID: 24483158
[TBL] [Abstract][Full Text] [Related]
15. Topical epidermal growth factor spray for the treatment of chronic diabetic foot ulcers: A phase III multicenter, double-blind, randomized, placebo-controlled trial.
Park KH; Han SH; Hong JP; Han SK; Lee DH; Kim BS; Ahn JH; Lee JW
Diabetes Res Clin Pract; 2018 Aug; 142():335-344. PubMed ID: 29902542
[TBL] [Abstract][Full Text] [Related]
16. Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: A prospective, randomized clinical trial.
Li L; Chen D; Wang C; Yuan N; Wang Y; He L; Yang Y; Chen L; Liu G; Li X; Ran X
Wound Repair Regen; 2015; 23(4):495-505. PubMed ID: 25847503
[TBL] [Abstract][Full Text] [Related]
17. NorLeu3-A(1-7) stimulation of diabetic foot ulcer healing: results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial.
Balingit PP; Armstrong DG; Reyzelman AM; Bolton L; Verco SJ; Rodgers KE; Nigh KA; diZerega GS
Wound Repair Regen; 2012; 20(4):482-90. PubMed ID: 22672145
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic assessment of diabetic foot ulcer debridement with collagenase: results of a randomized controlled study.
Tallis A; Motley TA; Wunderlich RP; Dickerson JE; Waycaster C; Slade HB;
Clin Ther; 2013 Nov; 35(11):1805-20. PubMed ID: 24145042
[TBL] [Abstract][Full Text] [Related]
19. Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.
Grek CL; Rhett JM; Bruce JS; Abt MA; Ghatnekar GS; Yeh ES
BMC Cancer; 2015 Apr; 15():296. PubMed ID: 25881004
[TBL] [Abstract][Full Text] [Related]
20. Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers.
Martínez-de Jesús FR; Morales-Guzmán M; Castañeda M; Pérez-Morales A; García-Alonso J; Mendiola-Segura I
Arch Med Res; 1997; 28(1):95-9. PubMed ID: 9078595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
